PA8634201A1 - Adenovirus quimericos para uso en el tratamiento del cancer - Google Patents

Adenovirus quimericos para uso en el tratamiento del cancer

Info

Publication number
PA8634201A1
PA8634201A1 PA20058634201A PA8634201A PA8634201A1 PA 8634201 A1 PA8634201 A1 PA 8634201A1 PA 20058634201 A PA20058634201 A PA 20058634201A PA 8634201 A PA8634201 A PA 8634201A PA 8634201 A1 PA8634201 A1 PA 8634201A1
Authority
PA
Panama
Prior art keywords
adenovirus
chemicals
cancer
treatment
oncolitical
Prior art date
Application number
PA20058634201A
Other languages
English (en)
Inventor
Paul Harden
Terry Hermiston
Irene Kuhn
Original Assignee
Schering Aktiengeselleschaft S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengeselleschaft S filed Critical Schering Aktiengeselleschaft S
Publication of PA8634201A1 publication Critical patent/PA8634201A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C12N15/8613—Chimaeric vector systems comprising heterologous sequences for production of another viral vector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

ADENOVIRUS ONCOLITICO CON APLICACIONES TERAPEUTICAS. SE PROVEEN ADENOVIRUS QUIMERICOS RECOMBINANTES Y METODOS PARA PRODUCIRLOS. LOS ADENOVIRUS QUIMERCIOS DE LA INVENCIÓNCOMPRENDEN SECUENCIAS DE ACIDO NUCLEICO DERIVADAS DE LOS SEROTIPOS ADENOVIRALES CLASIFICADOS EN LOS SUBGRUPOS B A F Y PRESENTAN UN INDICE TERAPEUTIC MEJORADO.
PA20058634201A 2004-05-26 2005-05-25 Adenovirus quimericos para uso en el tratamiento del cancer PA8634201A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57485104P 2004-05-26 2004-05-26

Publications (1)

Publication Number Publication Date
PA8634201A1 true PA8634201A1 (es) 2006-11-09

Family

ID=35355425

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20058634201A PA8634201A1 (es) 2004-05-26 2005-05-25 Adenovirus quimericos para uso en el tratamiento del cancer

Country Status (33)

Country Link
US (6) US7510868B2 (es)
EP (1) EP1749098B1 (es)
JP (1) JP4787936B2 (es)
KR (1) KR101169109B1 (es)
CN (3) CN1997746B (es)
AR (2) AR049188A1 (es)
AT (1) ATE491799T1 (es)
AU (1) AU2005250396B2 (es)
BR (2) BR122013008865B8 (es)
CA (2) CA2836987C (es)
CR (1) CR8794A (es)
DE (1) DE602005025340D1 (es)
DK (1) DK1749098T3 (es)
EC (1) ECSP067088A (es)
ES (1) ES2358204T3 (es)
GT (1) GT200500129A (es)
HK (3) HK1109421A1 (es)
HR (1) HRP20110179T1 (es)
IL (2) IL179098A (es)
MX (1) MXPA06013570A (es)
MY (1) MY140829A (es)
NO (1) NO340708B1 (es)
NZ (1) NZ551443A (es)
PA (1) PA8634201A1 (es)
PE (1) PE20060277A1 (es)
PL (1) PL1749098T3 (es)
PT (1) PT1749098E (es)
RU (1) RU2448157C2 (es)
TW (1) TWI366603B (es)
UA (1) UA89957C2 (es)
UY (1) UY28926A1 (es)
WO (1) WO2005118825A2 (es)
ZA (1) ZA200610763B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4787936B2 (ja) 2004-05-26 2011-10-05 サイオクサス セラピューティクス リミティド 癌処理への使用のためのキメラアデノウィルス
US20070258952A1 (en) * 2006-05-04 2007-11-08 Baylor Research Institute Anti-Tumor Activity of an Oncolytic Adenovirus-Delivered Oncogene siRNA
WO2008108890A2 (en) * 2006-10-18 2008-09-12 University Of Rochester Conditionally replicating viruses for cancer therapy
CA2667414C (en) 2006-11-13 2015-12-29 Sangamo Biosciences, Inc. Methods and compositions for modification of the human glucocorticoid receptor locus
EP2094284A2 (en) * 2006-12-22 2009-09-02 Bayer Schering Pharma AG Generation of oncolytic adenoviruses and uses thereof
KR100856310B1 (ko) 2007-02-28 2008-09-03 삼성전기주식회사 이동통신 단말기
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
CA2864956C (en) * 2012-03-12 2021-11-09 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
CN104334188B (zh) * 2012-03-22 2016-08-24 克鲁塞尔荷兰公司 抗rsv疫苗
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
KR20150122674A (ko) * 2013-02-28 2015-11-02 싸이오서스 테라퓨틱스 엘티디. 아데노바이러스의 생산 방법
CA2903582C (en) 2013-03-14 2021-06-08 Salk Institute For Biological Studies Oncolytic adenovirus compositions
CN112516179A (zh) * 2013-06-14 2021-03-19 普赛奥克苏斯治疗公司 用于b型腺病毒的给药方案及制剂
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
DK3021859T3 (en) * 2013-10-25 2018-03-05 Psioxus Therapeutics Ltd ONCOLYTIC ADENOVIRA EQUIPPED WITH HETEROLOGICAL GENES
GB2531821A (en) * 2013-10-25 2016-05-04 Psioxus Therapeutics Ltd Oncolytic adenoviruses armed with heterologous genes
GB201415579D0 (en) 2014-09-03 2014-10-15 Psioxus Therapeutics Ltd A process
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
GB201510197D0 (en) 2014-06-12 2015-07-29 Psioxus Therapeutics Ltd Method of treating ovarian cancer
EP3186366A2 (en) 2014-08-27 2017-07-05 Psioxus Therapeutics Limited A process for the production of adenovirus
MX2017013684A (es) * 2015-04-30 2018-08-28 Psioxus Therapeutics Ltd Adenovirus oncolitico que codifica una proteina b7.
JP7064437B2 (ja) 2015-12-17 2022-05-10 サイオクサス セラピューティクス リミテッド 抗ｔｃｒ複合体抗体又は断片をコードするｂ群アデノウイルス
EP4155411A1 (en) 2016-02-23 2023-03-29 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
US11273170B2 (en) * 2016-07-25 2022-03-15 Ascend Biopharmaceuticals Ltd Methods of treating cancer
WO2018041827A1 (en) 2016-08-29 2018-03-08 Psioxus Therapeutics Limited Adenovirus armed with bispecific t cell engager (bite)
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
WO2018083257A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083258A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018111767A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
JP7394628B2 (ja) 2017-06-01 2023-12-08 アカミス バイオ リミテッド 腫瘍溶解性ウイルスおよび方法
JP2020533976A (ja) 2017-09-05 2020-11-26 グラディエーター バイオサイエンシーズ インコーポレイテッド エキソソームを標的化する方法
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
WO2020106924A1 (en) 2018-11-21 2020-05-28 Mayo Foundation For Medical Education And Research Adenoviruses and methods for using adenoviruses
US11485767B2 (en) 2019-04-29 2022-11-01 Mayo Foundation For Medical Education And Research Multivalent PD-L1 binding compounds for treating cancer
GB201909081D0 (en) 2019-06-25 2019-08-07 Psioxus Therapeutics Ltd Method
WO2022170219A1 (en) 2021-02-05 2022-08-11 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
GB202102049D0 (en) 2021-02-13 2021-03-31 Psioxus Therapeutics Ltd Viruses

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5846945A (en) * 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
WO1995002697A1 (fr) 1993-07-13 1995-01-26 Rhone-Poulenc Rorer S.A. Vecteurs adenoviraux defectifs et utilisation en therapie genique
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US5677170A (en) 1994-03-02 1997-10-14 The Johns Hopkins University In vitro transposition of artificial transposons
US5877011A (en) 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
CN1242051A (zh) 1996-12-31 2000-01-19 昂尼克斯药物公司 用于肿瘤治疗和预防的致细胞病变病毒
EP1036183B1 (en) 1997-02-20 2007-10-03 The Johns Hopkins University School Of Medicine Mutations in atp-dependent transposition proteins that reduce target-site specificity
US6291214B1 (en) 1998-05-11 2001-09-18 Glaxo Wellcome Inc. System for generating recombinant viruses
US20020019051A1 (en) * 1998-05-27 2002-02-14 Monika Lusky Chimeric adenoviral vectors
US20030017138A1 (en) * 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
CN1110553C (zh) 1998-07-15 2003-06-04 杭州赛狮生物技术开发有限公司 基因工程腺病毒及其用途
KR100741247B1 (ko) * 1999-05-17 2007-07-19 크루셀 홀란드 비.브이. 아데노바이러스 타입 35의 적어도 하나의 구성성분을포함하는 아데노바이러스 유래 유전자 전달체
EP1083228A1 (en) * 1999-09-10 2001-03-14 Introgene B.V. Modified adenoviral vectors for use in gene therapy
US7396679B2 (en) * 1999-11-15 2008-07-08 Onyx Pharmaceuticals, Inc. Oncolytic adenovirus
JP2003534806A (ja) * 2000-05-31 2003-11-25 ジェンベク、インコーポレイティッド アデノウイルスベクターのターゲティングの方法および組成物
ATE449859T1 (de) * 2001-01-04 2009-12-15 Goeran Wadell Virusvektor zur gentherapie
WO2003092594A2 (en) * 2002-04-30 2003-11-13 Duke University Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
CN1327899C (zh) * 2003-05-10 2007-07-25 彭朝晖 腺病毒载体与p53基因的基因重组体的应用
JP4787936B2 (ja) 2004-05-26 2011-10-05 サイオクサス セラピューティクス リミティド 癌処理への使用のためのキメラアデノウィルス
EP1819823A2 (en) 2004-12-01 2007-08-22 Bayer Schering Pharma Aktiengesellschaft Generation of replication competent viruses for therapeutic use
EP2094284A2 (en) 2006-12-22 2009-09-02 Bayer Schering Pharma AG Generation of oncolytic adenoviruses and uses thereof

Also Published As

Publication number Publication date
CA2836987A1 (en) 2005-12-15
DE602005025340D1 (de) 2011-01-27
JP2008500051A (ja) 2008-01-10
UY28926A1 (es) 2006-01-31
US20130230902A2 (en) 2013-09-05
KR20070020302A (ko) 2007-02-20
RU2006145071A (ru) 2008-07-10
HK1179655A1 (en) 2013-10-04
AR049188A1 (es) 2006-07-05
JP4787936B2 (ja) 2011-10-05
GT200500129A (es) 2006-03-23
CN1997746A (zh) 2007-07-11
IL179098A0 (en) 2007-03-08
BR122013008865B1 (pt) 2020-11-24
ZA200610763B (en) 2009-06-24
TW200611974A (en) 2006-04-16
PL1749098T3 (pl) 2011-05-31
ATE491799T1 (de) 2011-01-15
HK1109421A1 (en) 2008-06-06
BRPI0510475B1 (pt) 2020-09-29
HRP20110179T1 (hr) 2011-04-30
CN102816742B (zh) 2014-04-09
TWI366603B (en) 2012-06-21
US20130209409A1 (en) 2013-08-15
BR122013008865B8 (pt) 2021-05-25
US20130217095A1 (en) 2013-08-22
US20150037874A1 (en) 2015-02-05
PE20060277A1 (es) 2006-05-25
CN104263703A (zh) 2015-01-07
CN1997746B (zh) 2012-09-26
BRPI0510475A (pt) 2007-11-06
IL226820A (en) 2017-07-31
US20120231524A1 (en) 2012-09-13
CA2567094C (en) 2014-11-25
CN104263703B9 (zh) 2019-12-17
DK1749098T3 (da) 2011-04-04
CN102816742A (zh) 2012-12-12
IL226820A0 (en) 2013-07-31
WO2005118825A2 (en) 2005-12-15
NO20066002L (no) 2006-12-22
CA2567094A1 (en) 2005-12-15
AR090647A2 (es) 2014-11-26
US20050265973A1 (en) 2005-12-01
BRPI0510475B8 (pt) 2021-05-25
WO2005118825A3 (en) 2006-11-23
US7510868B2 (en) 2009-03-31
MY140829A (en) 2010-01-29
US8158599B2 (en) 2012-04-17
UA89957C2 (ru) 2010-03-25
CR8794A (es) 2007-08-28
EP1749098A2 (en) 2007-02-07
IL179098A (en) 2015-09-24
KR101169109B1 (ko) 2012-07-26
EP1749098B1 (en) 2010-12-15
AU2005250396B2 (en) 2010-11-11
US20090227000A1 (en) 2009-09-10
CN104263703B (zh) 2018-01-09
US9115337B2 (en) 2015-08-25
NO340708B1 (no) 2017-06-06
US8765463B2 (en) 2014-07-01
NZ551443A (en) 2010-01-29
US9034344B2 (en) 2015-05-19
ES2358204T3 (es) 2011-05-06
AU2005250396A1 (en) 2005-12-15
PT1749098E (pt) 2011-02-02
HK1205529A1 (en) 2015-12-18
MXPA06013570A (es) 2007-02-08
RU2448157C2 (ru) 2012-04-20
ECSP067088A (es) 2007-01-26
CA2836987C (en) 2016-07-05
US9234185B2 (en) 2016-01-12

Similar Documents

Publication Publication Date Title
PA8634201A1 (es) Adenovirus quimericos para uso en el tratamiento del cancer
BR112019003866A2 (pt) adenovírus estimulado com fragmento de mab biespecífico com redirecionamento de células t (bite)
ECSP10010288A (es) Vectores de virus oncolíticos de viruela
CY1116015T1 (el) Καινοφανεις ενωσεις και μεθοδοι για θεραπεια
DOP2013000111A (es) Anticuerpos neutralizadores anti-ccl20
ECSP109878A (es) Anticuerpos anti-cd79b e inmunoconjugados y métodos de uso de los mismos
BR112019024813A2 (pt) adenovírus recombinantes portando transgenes
ECSP109940A (es) Anticuerpos anti-cd79b e inmunoconjugados humanizados y métodos de uso
MY181458A (en) Variant rnai
CY1116191T1 (el) Παραγωγα πυριδαζινονης
PE20130213A1 (es) Marcadores predictivos utiles en el tratamiento del sindrome fragil x (fxs)
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
BR112013004245A2 (pt) método, e, fluido espaçador
BR112015022625A8 (pt) microarranjo para entrega de agente terapêutico e métodos de utilização
NZ628213A (en) Adenoviruses expressing heterologous tumor-associated antigens
BR112017007430A2 (pt) conjuntos de reforço híbridos
ECSP10010287A (es) Vectores de virus oncolíticos de viruela
BR112014019142A2 (pt) composições e métodos para tratamento de superfícies com lipases
EA201301180A1 (ru) Основанная на bcma стратификация и терапия пациентов, страдающих множественной миеломой
UY31361A1 (es) Vacunas y componentes para inhibir celulas microbianas
BRPI0807132A2 (pt) enzimas para o tratamento de lignocelulósicos, ácidos nucléicos que codificam as mesmas, e metodos e uso das mesmas
AR006250A1 (es) Compuestos y metodos para la inmunoterapia e inmunodiagnostico del cancer prostatico
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
AR090318A1 (es) Lotes de adenovirus recombinantes con extremos terminales alterados
NO20100724L (no) Ledende sementformulering og anvendelse av denne i en bronn